Modality
Fusion Protein
MOA
FXIai
Target
AHR
Pathway
PD-1/PD-L1
SMAPsoriasis
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
May 2017
→ Feb 2029
Phase 3Current
NCT07209716
331 pts·SMA
2019-08→2029-02·Terminated
NCT07200293
340 pts·Psoriasis
2024-08→2026-04·Recruiting
NCT06766578
2,495 pts·Psoriasis
2017-05→2028-10·Not yet recruiting
3,166 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-04-01tomorrowPh3 Readout· Psoriasis
2028-10-282.6y awayPh3 Readout· Psoriasis
2029-02-182.9y awayPh3 Readout· SMA
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Not yet…
P3
Termina…
P3
Recruit…
Catalysts
Ph3 Readout
2026-04-01 · tomorrow
Psoriasis
Ph3 Readout
2028-10-28 · 2.6y away
Psoriasis
Ph3 Readout
2029-02-18 · 2.9y away
SMA
RecruitingTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07209716 | Phase 3 | SMA | Terminated | 331 | EASI-75 |
| NCT07200293 | Phase 3 | Psoriasis | Recruiting | 340 | UPDRS |
| NCT06766578 | Phase 3 | Psoriasis | Not yet recr... | 2495 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Pexanesiran | United Therapeutics | Phase 1 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR |